Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer: From Immunological Mechanisms to Clinical Evidence Publisher Pubmed



Farshbafnadi M1, 2 ; Pastaki Khoshbin A1, 2 ; Rezaei N3, 4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Sheffield, United Kingdom

Source: International Immunopharmacology Published:2021


Abstract

Breast cancer is the most common cancer type in women worldwide. Triple-negative breast cancer (TNBC), which is characterized by the absence of estrogen receptor/progesterone receptor (ER/PR) and human epidermal growth factor receptor 2 (Her2) expressions, has a poorer prognosis compared with non-TNBC breast tumors. Until recently systemic treatment for TNBC was confined to chemotherapy owing to the lack of actionable targets. Immune checkpoint molecules are expressed on malignant cells or tumor-infiltrating immune cells and can inhibit anti-cancer immune responses. Immune checkpoint inhibitors (ICI), including anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed cell death protein 1 (PD-1), and anti-programmed cell death 1 ligand 1 (PD-L1), induce immune responses in different types of neoplasms. They have recently gained attention for their possible role in TNBC treatment. Several clinical trials have been conducted on the role of immune checkpoint blockade in different settings for TNBC treatment. Available evidence justifies the application of ICI and chemotherapy combination in the management of metastatic TNBC and early-stage TNBC in neoadjuvant setting. This study aims to provide information on the mechanisms of action of ICIs, review the efficacy results of clinical trials using ICIs for TNBC treatment, and assess the side effects of such drugs. © 2021 Elsevier B.V.
Related Docs
View other Related Docs
1. Tumor Immunology, Clinical Immunology (2022)
2. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
3. The Tale of Tils in Breast Cancer: A Report From the International Immuno-Oncology Biomarker Working Group, npj Breast Cancer (2021)
4. Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Breast Cancer: A Systematic Review and Meta-Analysis, International Immunopharmacology (2021)
5. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
6. Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer, Immunotherapy (2021)
7. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
8. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (31)
Hamid Reza Mirzaei (1)
Other Related Docs
9. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
10. Immunopathology and Immunotherapy for Breast Cancer, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
11. Pdl1 Positivity Rate Between Triple-Negative and Non-Luminal Her2+ Cases, Current Cancer Therapy Reviews (2022)
12. Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review, Vaccines (2023)
13. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
14. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
15. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
16. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
17. Role of the Wnt and Gtpase Pathways in Breast Cancer Tumorigenesis and Treatment, Cytokine and Growth Factor Reviews (2022)
18. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
19. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
20. Role of Btla/Hvem Network in Development of Gastric Cancer, Human Immunology (2022)
21. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
22. Smart Bio-Encapsulation for Immunotherapy, Smart Nanomaterials for Bioencapsulation (2022)
23. Therapeutic and Immunomodulatory Potentials of Mesenchymal Stromal/Stem Cells and Immune Checkpoints Related Molecules, Biomarker Research (2024)
24. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
25. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
26. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
27. Cancer Immunoprevention: Current Status and Future Directions, Archivum Immunologiae et Therapiae Experimentalis (2021)
28. Current and Future Perspectives of Pd-1/Pdl-1 Blockade in Cancer Immunotherapy, Journal of Immunology Research (2021)
29. The Potential Role of Immunotherapy in Wilms’ Tumor: Opportunities and Challenges, Current Pharmaceutical Design (2023)
30. Expression of Pd1 and Pdl1 As Immune-Checkpoint Inhibitors in Mantle Cell Lymphoma, BMC Cancer (2022)
31. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
32. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
33. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
34. Adaptive Nk Cell Therapy Modulated by Anti-Pd-1 Antibody in Gastric Cancer Model, Frontiers in Pharmacology (2021)
35. Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma, Expert Review of Anticancer Therapy (2021)
36. Immune Checkpoint Inhibition in Covid-19: Risks and Benefits, Expert Opinion on Biological Therapy (2021)
37. Clinical Applications of Nanomedicine in Cancer Therapy, Drug Discovery Today (2020)
38. The Evolving Landscape of Predictive Biomarkers in Immuno-Oncology With a Focus on Spatial Technologies, Clinical and Translational Immunology (2020)
39. Shedding Light on the Side Effects of Immunotherapies Used for Leukemia: An Updated Review of the Literature, Expert Review of Anticancer Therapy (2023)
40. How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer, International Immunopharmacology (2020)
41. Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity, IUBMB Life (2021)
42. The Association Between Pd-1 Gene Polymorphisms and Susceptibility to Multiple Sclerosis, Immunological Medicine (2023)
43. Immunotherapy of Gastric and Esophageal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
44. Recent Progress in Cancer Immunotherapy: Overview of Current Status and Challenges, Pathology Research and Practice (2023)
45. Immune Microenvironment in Different Molecular Subtypes of Ductal Breast Carcinoma, Breast Cancer Research and Treatment (2021)
46. Immune Checkpoint Inhibition for Pancreatic Cancer, Acta Medica Iranica (2023)
47. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)
48. Understanding the Tumor Microenvironment for Effective Immunotherapy, Medicinal Research Reviews (2021)
49. Development and Clinical Application of Bispecific Antibody in the Treatment of Colorectal Cancer, Expert Review of Clinical Immunology (2020)
50. Functional Characterization and Development of Novel Human Kinase Insert Domain Receptor Chimeric Antigen Receptor T-Cells for Immunotherapy of Non-Small Cell Lung Cancer, European Journal of Pharmaceutical Sciences (2023)